MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical®, a medical device company harnessing the power of artificial intelligence to develop systems designed to automatically and continuously optimize insulin delivery for people living with insulin-requiring diabetes, today announced that the company has raised $37 million in the initial tranche of a Series B equity financing. The round is co-led by funds managed by a new investor, Janus Henderson Investors, along with Bigfoot’s largest existing investor, Quadrant Capital Advisors, Inc. Additionally, existing investors Cormorant Asset Management, Senvest Capital Inc., Senvest Management LLC, Visionnaire Ventures, JDRF T1D Fund and T1D Exchange also participated in the financing. This financing follows a previously announced $36 million Series A financing completed in 2016.
Insulin-requiring diabetes impacts over six million Americans, the vast majority of whom are not reaching clinical targets for optimal glucose levels. Insulin is a dangerous but life-saving drug that is potentially fatal when dosed incorrectly.
Funds will be used to support ongoing product development and clinical trials for Bigfoot’s investigational Class III medical device systems, which include Bigfoot Loop, an infusion pump-based closed loop automated insulin delivery system, and Bigfoot Inject, an auto-titrating connected insulin pen-based system for people on injection therapy.
“We are excited to announce Janus Henderson as a new partner in the financing of Bigfoot Biomedical, a category-defining company for digital health and medical devices. We also express our appreciation for our largest existing investor, Quadrant, as well as our gratitude for the expanded support of an impressive and expanding list of other world-class investors,” said Jeffrey Brewer, president and chief executive officer of Bigfoot Biomedical.
In July, Bigfoot Biomedical and Abbott announced that the companies had entered into an agreement to develop and commercialize diabetes management systems, integrating the highly successful Abbott FreeStyle® Libre glucose-sensing technology as the centerpiece for glucose monitoring capabilities within Bigfoot's ecosystem of insulin delivery solutions.
Bigfoot Biomedical recently presented data demonstrating that results from a feasibility study evaluating the company’s investigational automated system closely matched data gleaned from the company’s groundbreaking in silico metabolic simulation engine. The feasibility trial was completed in late 2016. The company anticipates a pivotal trial for Bigfoot Loop will begin in 2018 at clinical sites across the United States.
About Bigfoot Biomedical, Inc.
Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes. With its Loop and Inject services, the company seeks to reduce the burden of the disease on people with insulin-requiring diabetes and to maximize the leverage of health care providers through data, connectivity, automation, and artificial intelligence. Learn more at BigfootBiomedical.com. Follow us on Twitter @BigfootBiomed and Facebook.
About Quadrant Capital Advisors, Inc.
Quadrant Capital Advisors is the exclusive investment advisor to the family of the late Julio Mario Santo Domingo. The family has been invested for generations in the branded consumer goods sector and is today the third largest shareholder of Anheuser-Busch InBev SA/NV, the world's largest beer company.
About Janus Henderson Investors
Janus Henderson is a leading global active asset manager dedicated to helping investors achieve long-term financial goals through a broad range of investment solutions, including equities, quantitative equities, fixed income, multi-asset and alternative asset class strategies. As of 30 September 2017, Janus Henderson had approximately US $361 billion in assets under management, more than 2,000 employees and offices in 27 cities worldwide. Headquartered in London, the company is listed on the New York Stock Exchange (NYSE) and the Australian Securities Exchange (ASX).
